Evidence map›Paper›PMID 27999162›Full record

Trial reportmBio2016

Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.

Christopher Staley, Colleen R Kelly, Lawrence J Brandt, Alexander Khoruts, Michael J Sadowsky

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT)Canadian journal of gastroenterology & hepatology · 2019
    Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Christopher StaleyBioTechnology Institute, University of Minnesota, St. Paul, Minnesota, USA.
Colleen R KellyDepartment of Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Lawrence J BrandtDepartment of Medicine, Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Alexander KhorutsBioTechnology Institute, University of Minnesota, St. Paul, Minnesota, USA.
Michael J SadowskyBioTechnology Institute, University of Minnesota, St. Paul, Minnesota, USA sadowsky@umn.edu.ORCID 0000-0001-8779-2781
University of Minnesota · USAlbert Einstein College of Medicine · USBrown University · US

Funding

The role of bile acid metabolism recovery in treatment of C. difficile infectionR21AI114722 · NIAID · UNIVERSITY OF MINNESOTA · PI CHEN, CHI, KHORUTS, ALEXANDER · 2015 to 2016
$414k
NIAID NIH HHS R21 AI114722
6 · The paper itself

Abstract

Bacterial communities from subjects treated for recurrent Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation sequencing. As previously reported, the success of heterologous FMT (90%) was superior to that of autologous FMT (43%) (P = 0.019), and post-FMT intestinal bacterial communities differed significantly between treatment arms (P < 0.001). Subjects cured by autologous FMT typically had greater abundances of the Clostridium XIVa clade and Holdemania bacteria prior to treatment, and the relative abundances of these groups increased significantly after FMT compared to heterologous FMT and pre-FMT samples. The typical shift to post-FMT, donor-like assemblages, featuring high relative abundances of genera within the Bacteroidetes and Firmicutes phyla, was not observed in the autologous FMT subjects. Autologous FMT patient bacterial communities were significantly different in composition than those for heterologous FMT patients and donors (P < 0.001). The SourceTracker program, which employs a Bayesian algorithm to determine source contributions to sink communities, showed that patients initially treated by heterologous FMT had significantly higher percentages of engraftment (i.e., similarity to donor communities, mean value of 74%) compared to those who suffered recurrence following autologous FMT (1%) (P ≤ 0.013). The findings of this study suggest that complete donor engraftment may be not necessary if functionally critical taxa are present in subjects following antibiotic therapy. IMPORTANCE: This study provides a detailed characterization of fecal bacterial communities in subjects who participated in a previously published randomized clinical trial to treat recurrent C. difficile infection (rCDI). Bacterial communities were characterized to determine differences between subjects who received fecal bacteria either from healthy donor stool samples or their own stool samples as "placebo" in order to determine which groups of bacteria were most important in achieving a cure. The results of this study suggested that bacteria associated with secondary bile acid metabolism could potentially provide resistance to infection and that complete transfer of healthy donor microorganisms was not necessary to resolve CDI following unsuccessful antibiotic treatment.

Indexed as

AdultAgedBacillotaBacteroidetesBayes TheoremClinical Trials as TopicClostridioides difficileClostridium InfectionsDiarrheaFecal Microbiota TransplantationFecesFemaleGastrointestinal MicrobiomeHealthy VolunteersHigh-Throughput Nucleotide SequencingHumans

Identifiers

PMID27999162
PMCPMC5181777
OpenAlexW2567261527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.